Incorporation of 3'-azido-3'-deoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 22, Issue 5, 1999, Pages 477-483

  Poirier, Miriam C ^a   Patterson, Tucker A ^b   Slikker Jr , William ^b   Olivero, Ofelia A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

DNA incorporation; Monkey; Pharmacokinetics; Transplacental; Zidovudine

Indexed keywords

CELL DNA; ZIDOVUDINE; ZIDOVUDINE GLUCURONIDE;

AMNION FLUID LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; FEMALE; FETUS; GENOTOXICITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACACA; NONHUMAN; PLACENTAL TRANSFER; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; TRIXIS;

EID: 0033572374     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-199912150-00008     Document Type: Article

References (33)

1. Mofenson L. Antiretroviral therapy and interruption of HIV perinatal transmission. Immunol Allergy Clin North Am 1998;18:441-63.
2. O'Shea S, Newell ML, Dunn DT, et al. Maternal viral load, CD4 cell count and vertical transmission of HIV-1. J Med Virol 1998; 54:113-7.
3. The European Collaborative Study. Therapeutic and other interventions to reduce the risk of mother-to-child transmission of HIV-1 in Europe. Br J Obstet Gynaecol 1998;105:704-9.
4. Newell ML. Mechanisms and timing of mother-to-child transmission of HIV-1 [editorial]. AIDS 1998;12:831-7.
5. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
6. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996;335:1621-9.
7. Ayers KM, Clive D, Tucker WE, Hajian G, De Miranda P. Non-clinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fund Appl Toxicol 1996;32:148-58.
8. National Toxicology Program. Toxicology and carcinogenesis studies of AZT. Research Triangle Park, NC: National Toxicology Program, 1996.
9. Ayers KM, Torrey CE, Reynolds DJ. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Fund Appl Toxicol 1997;38:195-8.
10. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997;89:1602-8.
11. Diwan BA, Riggs CW, Logsdon D, et al. Multiorgan transplacental and neonatal carcinogenicity of 3′-azido-3′-deoxythymidine in mice. Tox Appl Pharmacol 1999;161:82-99.
12. Zhang Z, Diwan BA, Anderson LM, et al. Skin tumorigenesis and Ki-ras and Ha-ras mutations in tumors from adult mice exposed in utero to 3′-azido-2′,3′-dideoxythymidine. Mol Carcinog 1998;23: 45-51.
13. Olivero OA, Shearer GM, Chougnet CA, et al. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS 1999;13:919-25.
14. Patterson TA, Binienda ZK, Lipe GW, Gillam MP, Slikker W Jr, Sandberg JA. Transplacental pharmacokinetics and fetal distribution of azidothymidine, its glucuronide, and phosphorylated metabolites in late-term rhesus macaques after maternal infusion. Drug Metab Dispos 1997;25:453-9.
15. Qian M, Bui T, Ho RJ, Unadkat JD. Metabolism of 3′-azido-3′-deoxythymidine (AZT) in human placental trophoblasts and Hofbauer cells. Biochem Pharmacol 1994;48:383-9.
16. Flamm WG, Birnstiel ML, Walker PMB. Preparation and fractionation and isolation of single strands of DNA by ultracentrifugation in fixed-angle rotors. In Birnie GD, Fox SM, eds. Subcellular components: preparation and fractionation. London: Butterworths, 1967;126-54.
17. O'Sullivan MJ, Boyer PJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 1993;168:1510-6.
18. Tuntland T, Odinecs A, Nosbisch C, Unadkat JD. In vivo maternal-fetal-amniotic fluid pharmacokinetics of zidovudine in the pig-tailed macaque: comparison of steady-state and single-dose regimens [published erratum appears in J Pharmacol Exp Ther 1998; 286:1495]. J Pharmacol Exp Ther 1998;285:54-62.
19. Hankins GD, Lowery CL Jr, Scott RT, et al. Transplacental transfer of zidovudine in the near-term pregnant baboon. Am J Obstet Gynecol 1990;163:728-32.
20. Pons JC, Taburet AM, Singlas E, Delfraissy JF, Papiernik E. Placental passage of AZT during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Eur J Obstet Gynecol Reprod Biol 1991;40:229-31.
21. Gillet JY, Bongain A, Abrar D, Garraffo R, Lapalus P. Étude préliminaire sur le passage transplacentaire de l'AZT (retrovir) [in French: preliminary study on the transport of AZT (retrovirzidovudine) through the placenta]. J Gynecol Obstet Biol Reprod (Paris) 1990;19:177-80.
22. Lopez-Anaya A, Unadkat JD, Schumann LA, Smith AL. Pharmacokinetics of zidovudine (azidothymidine). I. Transplacental transfer. J Acquir Immune Defic Syndr 1990;3:959-64.
23. Garland M, Szeto HH, Daniel SS, Tropper PJ, Myers MM, Stark RI. Implications of the kinetics of zidovudine in the pregnant baboon following oral administration. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:433-40.
24. Sperling RS, Roboz J, Dische R, Silides D, Holzman I, Jew E. Zidovudine pharmacokinetics during pregnancy. Am J Perinatol 1992;9:247-9.
25. Mirochnick M, Capparelli E, Dankner W, Sperling RS, van Dyke R, Spector SA. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. Antimicrob Agents Chemother 1998;42:808-12.
26. Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993;122:137-44.
27. Dertinger SD, Torous DK, Tometsko KR. Induction of micronuclei by low doses of azidothymidine (AZT). Mutat Res 1996;368: 301-7.
28. Stern M, Cid MG, Larripa I, Slavutsky I. AZT-induction of micronuclei in human lymphocyte subpopulations. Toxicol Lett 1994; 70:235-42.
29. Gonzalez CM, Larripa I. Genotoxicity of azidothymidine (AZT) in in vitro systems. Mutat Res 1994;321:113-8.
30. Olivero OA, Beland FA, Fullerton NF, Poirier MC. Vaginal epithelial DNA damage and expression of preneoplastic markers in mice during chronic dosing with tumorigenic levels of 3′-azido-2′,3′-dideoxythymidine (AZT). Cancer Res 1994;54:6235-42.
31. Shafik HM, Nokta MA, Pollard RB. Recombinant human interferon beta ser protects against zidovudine-induced genetic damage in AIDS patients. Antiviral Res 1991;16:205-12.
32. Grdina DJ, Dale P, Weichselbaum R. Protection against AZT-induced mutagenesis at the HGPRT locus in a human cell line by WR-151326. Int J Radiation Oncol Biol Phys 1992;22:813-5.
33. Sussman HE, Olivero OA, Pietras SM, et al. Genotoxicity of 3′-azido-3′-deoxythymidine (AZT) in the human lymphoblastoid cell line TK6: relationship between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT. Mutat Res 1999;429:249-59.